Fed Circuit split over $235m skinny label verdict

The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Fed Circ to rehear $235m ‘skinny label’ case

10 February 2021 The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.

Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

14 February 2022 A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Big Pharma

Fed Circ to rehear $235m ‘skinny label’ case

Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

14 February 2022 A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.

More on this story

Big Pharma

Fed Circ to rehear $235m ‘skinny label’ case

Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

14 February 2022 A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Americas

Teva takes long-running ‘skinny label’ suit to SCOTUS

14 July 2022 Generics giant’s petition cites the cost of medicine and first-principles of innovation.